AGEN 1884

Drug Profile

AGEN 1884

Alternative Names: AGEN-1884

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 4-Antibody; Ludwig Institute for Cancer Research
  • Developer Agenus; Recepta biopharma
  • Class Antineoplastics; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Cancer

Most Recent Events

  • 16 Mar 2018 Agenus has issued and pending patents for Retrocyte Display™ technology platform in USA
  • 08 Jan 2018 Agenus plans to file BLA in the second half of 2019
  • 01 Dec 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top